Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
Ravi Prakash Rao
Ansima Singh
Arun Kjain
Bhartu Parsharthi Srinivasan
摘要：Diabetic nephropathy is a major cause of end-stage renal disease (ESRD) in the general population.It is estimated that diabetic nephropathy will eventually develop in about 40％ of all patients with diabetes; therefore,prevention is critical for delaying the development and progression of diabetic kidney disease.Despite extensive efforts,medical advances are still not successful enough to prevent the progression of the disease.In the present study,we focused on the comparison of combination therapies and whether they offered additional renoprotection.Type 2 diabetes mellitus was induced by intraperitoneally administering streptozotocin (90 mg/kg) in neonatal rats and then these rats were treated with rosiglitazone (1.0 mg/kg) in combination with glimepiride (0.5 mg/kg) or with pioglitazone (2.5 mg/kg) in combination with glimepiride (0.5 mg/kg).Diabetic nephropathy markers were evaluated by biochemical and ELISA kits and renal structural changes were examined by light microscopy and transmission electron microscopy.Results show that the combination of pioglitazone with glimepiride is more effective in amelioration of diabetic nephropathy than rosiglitazone with glimepiride drug therapy due to glycemic control,suppressing albumin excretion rate,total protein excretion rate and augmented TNF-a signaling during the development of streptozotocin induced type 2 diabetic nephropathy.
机标关键词：typediabetic nephropathycombinationdevelopmentstructural changesdiabetes mellituslight microscopyrenal disease
分类号：R587.1(内分泌腺疾病及代谢病)
论文发表日期：2011-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
英文信息